Release Date
On May 26, 2016, the Food and Drug Administration (FDA) approved the buprenorphine implant Probuphine for the treatment of opioid addiction. Probuphine consists of four small implants that are inserted into the upper arm and deisnged to provide a constant, low level dose of buprenorphine in patients who are already stable on low-to-moderate doses of other forms of buprenorphine.
